Clariant is expanding its capabilities for the Hostapon SCI brand of isethionate derivatives at its site in Mount Holly, US, and Tarragona, Spain. This will comprise both capacity increases and modernisation via optimised energy consumption and aggregate options for new SI grades. It should come onstream during Q1 2021.
Six days after the US and the UK began formal negotiations for a post-Brexit bilateral trade deal on 5 May, representatives from the respective industry associations, the American Chemistry Council (ACC) and the Chemical Industries Association (CIA) jointly published some comments outlining their priorities.
“With the uncertainty swirling around Brexit and the COVID-19 crisis, a trade agreement between the UK and the USA will help ensure both countries maintain critical market access during this unprecedented and challenging time,” said Steve Elliott, chief executive of the CIA.
Several of the world’s major pharmaceutical CDMOS have recently made announcements relating to their participation in projects to develop treatment for the Covid-19 virus. Many involve chloroquines, in anticipation of their large-scale use.
Skin care giant Beiersdorf and Evonik have agreed a research partnership to develop sustainable raw materials for personal care products via artificial photosynthesis, using CO2 as the starting material, along with water, solar energy and bacteria. The two companies described this part of their ongoing efforts to reduce their carbon footprints and becoming carbon-positive.
Bachem, the world’s largest producer of pharmaceutical peptides and ologonucleotides, has signed an exclusive licensing agreement with Japanese firm Jitsubo related to the latter’s liquid-phase peptide technology. Molecular Hiving. Financial terms were not disclosed. The two firms have already worked together on APIs and cosmetic peptides.
Roger-Marc Nicoud, CEO of Ypso-Facto, looks at the challenges and opportunities for CDMOs in the current crisis*
The current crisis has highlighted the dependence of European and, indeed, North American countries on delocalised production. This is the case for many goods, including APIs and drugs in general.
Evonik, which is one of the world’s largest pharmaceutical CDMOs, has announced the €25 million first stage of a long-term programme to expand API and advanced intermediates capacity at its sites in Dossenheim and Hanau, Germany. This should be completed by mid-2021 and the whole project should be finalised prior to 2024.